Bioventus BVS
NASDAQ BVS
$13.64 -0.19 (-1.41%)
As of: Sep 9, 2026 · 3:59 PM EDT

Bioventus (BVS) Income from Discontinued Operations (2022 - 2023)

Bioventus' (BVS) quarterly Income from Discontinued Operations came in at -$74.4 million in Q2 2023, down 18460.85% on a YoY basis from N/an in Q2 2022, and down 218.13% quarter-over-quarter from -$23.4 million in Q4 2022.

Analysis

Bioventus (BVS) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

Bioventus (BVS) has reported Income from Discontinued Operations for 2 consecutive years, with -$74.4 million the latest figure, recorded in Q2 2023.

  • For the quarter ending Q2 2023, Income from Discontinued Operations fell 18460.85% year-over-year to -$74.4 million; the trailing twelve-month figure through Dec 2023 stood at -$74.4 million (down 8.28% YoY), and the FY2023 full-year result was -$74.4 million, down 8.28% from the prior year.
  • Income from Discontinued Operations retreated to -$74.4 million in Q2 2023 per BVS's latest filing, from -$23.4 million in the prior quarter.
  • Across five years, Income from Discontinued Operations topped out at -$280000.0 in Q3 2022 and bottomed at -$74.4 million in Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn -
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn -
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn -
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn -
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn -
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn -
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn -
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn -
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn -
10 Bioventus 923.70 Mn 894.24 Mn 105.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 1, 2023 -74.43 Mn
Dec 31, 2022 -23.40 Mn
Oct 1, 2022 -44.66 Mn
Jul 2, 2022 -280,000.00
Apr 2, 2022 -401,000.00